Humana (NYSE:HUM) Rating Lowered to Strong Sell at Zacks Research

Humana (NYSE:HUM) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Humana’s Q1 2027 earnings at $8.98 EPS, Q2 2027 earnings at $6.34 EPS and Q3 2027 earnings at $0.70 EPS.

A number of other research firms have also recently commented on HUM. Barclays reduced their price target on Humana from $245.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Robert W. Baird reduced their price target on Humana from $264.00 to $205.00 and set a “neutral” rating for the company in a report on Wednesday. Cantor Fitzgerald reduced their price target on Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a report on Thursday, February 12th. UBS Group reiterated a “neutral” rating on shares of Humana in a report on Wednesday, February 25th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $344.00 price target on shares of Humana in a report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $222.09.

Humana Trading Up 1.0%

Humana stock opened at $198.20 on Tuesday. Humana has a 52 week low of $163.11 and a 52 week high of $315.35. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a market capitalization of $23.79 billion, a P/E ratio of 20.18, a PEG ratio of 2.10 and a beta of 0.44. The stock has a 50-day simple moving average of $180.95 and a 200 day simple moving average of $231.53.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. During the same quarter last year, the company posted ($2.16) earnings per share. Humana’s quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Analysts expect that Humana will post 16.47 earnings per share for the current year.

Insiders Place Their Bets

In other Humana news, insider Sanjay K. Shetty acquired 810 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider directly owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Montag A & Associates Inc. boosted its stake in shares of Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the period. CoreCap Advisors LLC lifted its position in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana during the 4th quarter valued at $27,000. Reflection Asset Management bought a new stake in shares of Humana during the 4th quarter valued at $29,000. Finally, Rosenberg Matthew Hamilton raised its stake in Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after purchasing an additional 68 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Truist raised its price target for HUM to $220, signaling some analyst confidence that limits downside from current levels. Truist Increases Humana Price Target
• Positive Sentiment: Humana announced a partnership with Tuesday Health to expand value?based palliative care starting June 1 — a growth/strategy positive that supports Medicare Advantage membership engagement and value?based care positioning. Tuesday Health Partnership
• Positive Sentiment: Humana research (with UChicago Medicine) published results showing phone-based inhaler training improved COPD member medication use — evidence of effective care management that can reduce costs and improve outcomes in Humana’s Medicare Advantage population. COPD Inhaler Study
• Neutral Sentiment: Humana’s Board declared a quarterly cash dividend of $0.885 per share (payable July 31; record June 26) — supports income investors but is routine and offers a modest ~1.8% yield. Dividend Declaration
• Negative Sentiment: Robert W. Baird cut its price target on HUM from $264 to $205 and kept a neutral rating — a meaningful trim that reduces upside expectations and can pressure shares. Baird Lowers Price Target TickerReport
• Negative Sentiment: Zacks Research trimmed Q1–Q3 2027 EPS estimates slightly (Q1 to $8.98, Q2 to $6.34, Q3 to $0.70) and maintains a “Strong Sell” rating, signaling bearish analyst conviction and downward pressure on expectations for near-term earnings. (No direct Zacks link provided in the feed.)

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.